Corvus Pharmaceuticals Achieves Clinical Breakthrough – Soquelitinib Takes Center Stage
Reading Time: 2 minutes
Corvus Pharmaceuticals is a clinically-oriented biopharmaceutical company based in the USA that develops novel therapies for the treatment of immune and cancer diseases. The company's focus is on the discovery and development of targeted agents that regulate proteins crucial for the maturation and function of immune cells. Leading the way is the orally available drug candidate soquelitinib, a selective inhibitor of the ITK kinase, which is currently being tested in clinical trials for the treatment of dermatitis and other immunological diseases....
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
